China-based vaccines specialist CanSino Biotechnology Inc., (HKG: 6185) has announced plans to invest RMB 140 million (USD 20.3 million) in the establishment of a private equity fund with a total value of RMB 500 million (USD 72.5 million). The fund will focus on investments in vaccine companies, highlighting CanSino’s commitment to expanding its footprint in the global vaccine industry.
Collaboration with Tianjin Biotech Firms
Other investors in the fund include Tianjin Jiurui Biotechnology Co., Ltd and Tianjin Lisheng Pharmaceutical Co., Ltd, both of which are significant players in the biotechnology sector. This collaboration aims to leverage the expertise and resources of each participant to identify and support innovative vaccine companies that have the potential to shape the future of healthcare.
Strategic Investment in the Vaccine Industry
The establishment of this private equity fund underscores CanSino Biotechnology’s strategic approach to investing in the vaccine sector. By partnering with other industry players, the company is well-positioned to capitalize on emerging opportunities and contribute to the development of new vaccines that address unmet medical needs.-Fineline Info & Tech
